Ultimovacs (OSE: ULTI)

Last close As at 20/05/2024

NOK7.35

0.00 (0.00%)

Market capitalisation

NOK253m

Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

View More

Healthcare | Flash note

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare | Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare | edison tv

Ultimovacs – executive interview

Ultimovacs_resized

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Carlos de Sousa

    CEO

  • Gustav Gaudernack

    CSO

  • Hans Vassgård Eid

    CFO

  • Jens Bjørheim

    CMO

  • Ton Berkien

    CBO

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (27.2) (94.6) (94.0)
Relative (29.6) (95.1) (94.8)
52 week high/low NOK160.4/NOK6.3

Financials

Ultimovacs is focused on developing a cancer vaccine with universal potential. Lead asset UV1 activates the immune system to recognise cancer cells that express hTERT, which is present in c 85–90% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total, with readouts across 2023–25. While UV1 has demonstrated efficacy in mesothelioma (NIPU), recent results in melanoma (INITIUM) did not show the expected added benefit with UV1. The next readouts in head and neck cancer (FOCUS) are expected in Q324.

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 0.0 (181.0) (167.8) (489.9) N/A N/A
2023A 0.0 (213.0) (189.2) (550.1) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Line of sight on INITIUM top-line readout

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Two for two in melanoma Phase I trial

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — UV1 ODD a sign of positive things to come

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Positive Phase I update in malignant melanoma

Update

Healthcare

Ultimovacs — UV1 by no means out after NIPU readout

Update

Healthcare

Ultimovacs — On track for upcoming UV1 catalysts

edison tv

Healthcare

Ultimovacs – executive interview

edison tv

Healthcare

Ultimovacs – executive interview

Flash note

Healthcare

Ultimovacs — Further positivity for UV1

Update

Healthcare

Ultimovacs — UV1 development funded past key readouts

Flash note

Healthcare

Ultimovacs — Patient expansion in Phase I TENDU

Flash note

Healthcare

Ultimovacs — Positive Phase I survival data in melanoma

Flash note

Healthcare

Ultimovacs — UV1 Phase II data flow creeps closer

edison tv

Healthcare

Ultimovacs – executive interview

edison tv

Healthcare

Ultimovacs – executive interview Test

Update

Healthcare

Ultimovacs — New large indication for UV1

edison tv

Healthcare

Ultimovacs – Edison Open House interview

QuickView

Healthcare

Ultimovacs — Phase II data from 500+ patients over 2022/23

QuickView

Healthcare

Ultimovacs — Cancer vaccine with near-universal potential